

Joaquin Martinez-Lopez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1393034/publications.pdf>

Version: 2024-02-01

464
papers

15,860
citations

31902

53
h-index

22102

113
g-index

476
all docs

476
docs citations

476
times ranked

15359
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 754-766.	13.9	1,246
2	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2018, 378, 518-528.	13.9	747
3	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 27-38.	5.1	723
4	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1055-1066.	5.1	710
5	Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. <i>Leukemia</i> , 2017, 31, 2094-2103.	3.3	486
6	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. <i>Lancet Oncology</i> , The, 2018, 19, 747-757.	5.1	444
7	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. <i>Blood</i> , 2012, 120, 1589-1596.	0.6	429
8	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 934-941.	5.1	427
9	Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. <i>Nature Genetics</i> , 2014, 46, 107-115.	9.4	410
10	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. <i>Blood</i> , 2014, 123, 3073-3079.	0.6	380
11	High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. <i>Blood</i> , 2012, 119, 687-691.	0.6	274
12	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 5775-5782.	0.8	263
13	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 2900-2910.	0.8	248
14	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1959-1970.	0.8	228
15	Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1627-1633.	0.8	202
16	Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. <i>Blood</i> , 2011, 118, 529-534.	0.6	183
17	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. <i>Nature Medicine</i> , 2022, 28, 325-332.	15.2	182
18	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2021, 397, 2361-2371.	6.3	177

#	ARTICLE	IF	CITATIONS
19	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 784-792.	0.8	175
20	Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 133.	6.9	171
21	Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. <i>Leukemia</i> , 2014, 28, 391-397.	3.3	155
22	IL-6-based mortality risk model for hospitalized patients with COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 799-807.e9.	1.5	154
23	Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. <i>Blood</i> , 2012, 120, 2581-2588.	0.6	148
24	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , 2020, 136, 3033-3040.	0.6	146
25	Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. <i>Haematologica</i> , 2005, 90, 1365-72.	1.7	135
26	Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. <i>Haematologica</i> , 2013, 98, 79-86.	1.7	132
27	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. <i>Blood</i> , 2016, 127, 3165-3174.	0.6	129
28	Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. <i>Leukemia</i> , 2014, 28, 1334-1340.	3.3	115
29	hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. <i>Cancer Cell</i> , 2015, 28, 486-499.	7.7	110
30	Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>Blood</i> , 2019, 134, 421-431.	0.6	110
31	Busulfan 12 mg/kg plus melphalan 140 mg/m ² versus melphalan 200 mg/m ² as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. <i>Haematologica</i> , 2010, 95, 1913-1920.	1.7	101
32	Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. <i>British Journal of Haematology</i> , 2000, 109, 438-446.	1.2	100
33	The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. <i>Cancers</i> , 2021, 13, 217.	1.7	99
34	Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. <i>Leukemia</i> , 2006, 20, 1047-1054.	3.3	95
35	GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. <i>Blood</i> , 2014, 124, 1887-1893.	0.6	95
36	Spectrum and functional validation of PSMB5 mutations in multiple myeloma. <i>Leukemia</i> , 2019, 33, 447-456.	3.3	93

#	ARTICLE	IF	CITATIONS
37	Differentiation stage of myeloma plasma cells: biological and clinical significance. <i>Leukemia</i> , 2017, 31, 382-392.	3.3	83
38	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. <i>Blood</i> , 2021, 137, 49-60.	0.6	80
39	A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. <i>Leukemia</i> , 2013, 27, 2056-2061.	3.3	78
40	Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission. <i>Clinical Cancer Research</i> , 2013, 19, 4770-4779.	3.2	77
41	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. <i>Blood</i> , 2020, 136, 199-209.	0.6	76
42	Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. <i>Leukemia</i> , 2012, 26, 1862-1869.	3.3	73
43	Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. <i>European Journal of Haematology</i> , 2020, 105, 597-607.	1.1	73
44	Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma. <i>OncImmunity</i> , 2016, 5, e1250051.	2.1	71
45	Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. <i>British Journal of Haematology</i> , 2000, 109, 138-147.	1.2	69
46	Age at Onset Should Be a Major Criterion for Subclassification of Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 116-126.	1.2	68
47	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. <i>Haematologica</i> , 2015, 100, 1327-1333.	1.7	68
48	Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells. <i>Clinical Cancer Research</i> , 2017, 23, 5824-5835.	3.2	67
49	NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 146.	2.8	67
50	Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs. <i>Journal of Clinical Oncology</i> , 2011, 29, 2543-2549.	0.8	64
51	Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. <i>Leukemia</i> , 2017, 31, 1922-1927.	3.3	63
52	Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. <i>British Journal of Haematology</i> , 2016, 172, 786-793.	1.2	60
53	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 108.	2.8	60
54	Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. <i>Blood Cancer Journal</i> , 2020, 10, 103.	2.8	57

#	ARTICLE	IF	CITATIONS
55	Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. <i>Blood</i> , 2016, 128, 2241-2252.	0.6	54
56	Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. <i>Blood</i> , 2011, 118, 4547-4553.	0.6	53
57	Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. <i>Haematologica</i> , 2012, 97, 1020-1028.	1.7	53
58	Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-oligonucleotide polymerase chain reaction: the prognostic impact of achieving molecular response. <i>British Journal of Haematology</i> , 2008, 142, 766-774.	1.2	52
59	Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. <i>Haematologica</i> , 2017, 102, 103-109.	1.7	52
60	The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. <i>Haematologica</i> , 2014, 99, e55-e57.	1.7	51
61	Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. <i>Leukemia</i> , 2016, 30, 1844-1852.	3.3	51
62	Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. <i>Blood</i> , 2016, 127, 420-425.	0.6	51
63	Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients. <i>BMC Gastroenterology</i> , 2012, 12, 114.	0.8	50
64	Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. <i>Blood</i> , 2015, 126, 858-862.	0.6	50
65	Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. <i>Cancer Letters</i> , 2018, 422, 107-117.	3.2	49
66	High Resolution Melting Analysis for JAK2 Exon 14 and Exon 12 Mutations. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 155-161.	1.2	48
67	Treatment for patients with newly diagnosed multiple myeloma in 2015. <i>Blood Reviews</i> , 2015, 29, 387-403.	2.8	48
68	Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 2002, 43, 67-75.	0.6	45
69	GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy. <i>Frontiers in Immunology</i> , 2019, 10, 2361.	2.2	45
70	Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, 1334-1339.	1.7	44
71	Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. <i>Leukemia</i> , 2017, 31, 1446-1449.	3.3	44
72	Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. <i>Annals of Hematology</i> , 2008, 87, 741-749.	0.8	43

#	ARTICLE	IF	CITATIONS
73	Prognostic significance of copy number alterations in adolescent and adult patients with precursor <sc>B</sc> acute lymphoblastic leukemia enrolled in <sc>PETHEMA</sc> protocols. <i>Cancer</i> , 2015, 121, 3809-3817.	2.0	43
74	Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2832.	1.8	42
75	Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. <i>Leukemia</i> , 2020, 34, 589-603.	3.3	41
76	IKZF1/3 and CRL4^{CRBN} E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. <i>Haematologica</i> , 2020, 105, e237-e241.	1.7	41
77	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3151-3161.	0.8	40
78	Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2016, 175, 448-456.	1.2	39
79	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. <i>Nature Communications</i> , 2015, 6, 7539.	5.8	38
80	Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. <i>Oncotarget</i> , 2017, 8, 106948-106961.	0.8	38
81	Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. <i>Leukemia</i> , 2018, 32, 971-978.	3.3	38
82	Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. <i>Blood</i> , 2019, 134, 781-781.	0.6	38
83	Clofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 46-48.	0.6	38
84	Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study. <i>Journal of Medical Virology</i> , 2021, 93, 831-842.	2.5	37
85	Breast Cancer-Specific mRNA Transcripts Presence in Peripheral Blood After Adjuvant Chemotherapy Predicts Poor Survival Among High-Risk Breast Cancer Patients Treated With High-Dose Chemotherapy With Peripheral Blood Stem Cell Support. <i>Journal of Clinical Oncology</i> , 2006, 24, 3611-3618.	0.8	36
86	A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 288-296.	1.7	36
87	Clinical significance of Gata1, Gata2, EKLF, and cMPL expression in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2009, 84, 79-86.	2.0	34
88	Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. <i>Blood</i> , 2016, 127, 3035-3039.	0.6	34
89	Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. <i>British Journal of Cancer</i> , 2017, 117, 256-265.	2.9	34
90	Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 181, 397-400.	1.2	34

#	ARTICLE	IF	CITATIONS
91	Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. <i>Blood</i> , 2017, 129, 2233-2245.	0.6	33
92	Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 853-861.	2.0	33
93	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. <i>Leukemia</i> , 2019, 33, 2324-2330.	3.3	33
94	Protein Carbonylation and Lipid Peroxidation in Hematological Malignancies. <i>Antioxidants</i> , 2020, 9, 1212.	2.2	33
95	Clinical Correlation of a Precision Medicine Test with Treatment Outcome in Acute Myeloid Leukemia Patients. <i>Blood</i> , 2020, 136, 1-2.	0.6	33
96	Deep Response in Multiple Myeloma: A Critical Review. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	32
97	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. <i>Lancet Haematology</i> , 2022, 9, e98-e110.	2.2	32
98	Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Mieloma de Fase II trial. <i>British Journal of Haematology</i> , 2003, 120, 296-303.	1.2	31
99	Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients. <i>BMC Gastroenterology</i> , 2011, 11, 130.	0.8	31
100	Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. <i>Leukemia</i> , 2013, 27, 925-931.	3.3	31
101	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2358-2370.	3.3	31
102	Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 305-318.	0.2	30
103	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. <i>International Journal of Cancer</i> , 2015, 136, E351-8.	2.3	30
104	Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 896-896.	0.6	29
105	Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients. <i>American Journal of Hematology</i> , 2016, 91, 700-704.	2.0	28
106	Clinical applicability and prognostic significance of molecular response assessed by fluorescent PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. <i>British Journal of Haematology</i> , 2013, 163, 581-589.	1.2	27
107	Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. <i>Annals of Hematology</i> , 2016, 95, 2033-2041.	0.8	27
108	Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. <i>Haematologica</i> , 2019, 104, e551-e554.	1.7	27

#	ARTICLE	IF	CITATIONS
109	HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF). <i>Blood</i> , 2014, 124, 710-710.	0.6	27
110	In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by $\hat{1}\pm 4\hat{1}^{21}$ cytoplasmic-binding proteins. <i>Leukemia</i> , 2016, 30, 861-872.	3.3	26
111	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. <i>Leukemia</i> , 2020, 34, 3007-3018.	3.3	26
112	Life-threatening nonspherocytic hemolytic anemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression. <i>Blood</i> , 2005, 106, 1851-1856.	0.6	25
113	Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis. <i>Haematologica</i> , 2014, 99, e098-e101.	1.7	25
114	Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 2160-2172.	1.3	25
115	Cereblon enhancer methylation and IMiD resistance in multiple myeloma. <i>Blood</i> , 2021, 138, 1721-1726.	0.6	25
116	Impact of COVID-19 in patients with multiple myeloma based on a global data network. <i>Blood Cancer Journal</i> , 2021, 11, 198.	2.8	25
117	Rapid Detection of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia Using High-Resolution Melting Analysis. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 458-463.	1.2	24
118	Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2019, 25, 369-377.	3.2	24
119	MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia. <i>Scientific Reports</i> , 2019, 9, 18630.	1.6	24
120	Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 228-240.	1.2	24
121	Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial. <i>Blood</i> , 2019, 134, 1584-1584.	0.6	24
122	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 135, 2375-2387.	0.6	24
123	Effect of folic acid treatment on carotid intima-media thickness of patients with coronary disease. <i>International Journal of Cardiology</i> , 2007, 118, 345-349.	0.8	23
124	Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. <i>European Journal of Haematology</i> , 2017, 98, 407-414.	1.1	23
125	Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. <i>Leukemia</i> , 2018, 32, 553-555.	3.3	23
126	Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. <i>Blood</i> , 2021, 138, 1901-1905.	0.6	23

#	ARTICLE	IF	CITATIONS
127	Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients. <i>International Journal of Laboratory Hematology</i> , 2021, 43, O152-O155.	0.7	23
128	Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials. <i>American Journal of Pathology</i> , 2012, 181, 1870-1878.	1.9	22
129	Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2017, 178, 764-771.	1.2	22
130	A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 99-106.	1.2	22
131	Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. <i>Hematological Oncology</i> , 2017, 35, 746-751.	0.8	22
132	Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas. <i>Journal of the National Cancer Institute</i> , 2020, 112, 95-106.	3.0	22
133	Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 118-126.	2.0	21
134	Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. <i>Annals of Hematology</i> , 2017, 96, 1069-1075.	0.8	21
135	Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 810-820.	1.5	21
136	The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. <i>PLoS ONE</i> , 2020, 15, e0237155.	1.1	21
137	Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. <i>Leukemia and Lymphoma</i> , 2021, 62, 2928-2938.	0.6	21
138	Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2163-2171.	2.5	21
139	Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation. <i>Journal of Clinical Pathology</i> , 2011, 64, 1010-1013.	1.0	20
140	Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. <i>Molecular Cancer</i> , 2013, 12, 142.	7.9	20
141	Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. <i>British Journal of Haematology</i> , 2013, 161, 667-676.	1.2	20
142	Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. <i>Leukemia</i> , 2019, 33, 1256-1267.	3.3	20
143	Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 3295-3301.	2.5	20
144	Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2020, 10, 89.	2.8	20

#	ARTICLE	IF	CITATIONS
145	First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 2308-2317.	3.2	20
146	NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells. <i>Blood</i> , 2018, 132, 590-590.	0.6	20
147	Long-term follow-up of donor chimerism and tolerance after human liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 581-591.	1.3	19
148	Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. <i>Haematologica</i> , 2015, 100, 1096-102.	1.7	19
149	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. <i>Haematologica</i> , 2016, 101, 872-878.	1.7	19
150	Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 96.	6.9	19
151	Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 126.	6.9	19
152	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. <i>Blood Advances</i> , 2022, 6, 690-703.	2.5	19
153	A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib. <i>Blood</i> , 2010, 116, 307-307.	0.6	19
154	Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial. <i>Blood</i> , 2021, 138, 466-466.	0.6	19
155	Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. <i>PLoS ONE</i> , 2018, 13, e0203392.	1.1	18
156	Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse. <i>Haematologica</i> , 2021, 106, 2325-2333.	1.7	18
157	Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. <i>Blood Advances</i> , 2021, 5, 760-770.	2.5	18
158	Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial. <i>Blood</i> , 2020, 136, 1-3.	0.6	18
159	Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3234-3239.	2.5	18
160	Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2016, 96, 285-290.	1.1	17
161	Upregulated expression and function of the $\alpha 4 \beta 1$ integrin in multiple myeloma cells resistant to bortezomib. <i>Journal of Pathology</i> , 2020, 252, 29-40.	2.1	17
162	An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study. <i>Blood</i> , 2015, 126, 827-827.	0.6	17

#	ARTICLE	IF	CITATIONS
163	Response to imatinib mesylate in patients with hypereosinophilic syndrome. <i>International Journal of Hematology</i> , 2012, 96, 320-326.	0.7	16
164	Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020, 10, 14.	2.8	16
165	Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy. <i>Cancers</i> , 2021, 13, 577.	1.7	16
166	A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2003-2014.	2.0	16
167	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. <i>Oncotarget</i> , 2016, 7, 59029-59048.	0.8	16
168	The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies. <i>Cancers</i> , 2022, 14, 1310.	1.7	16
169	<scp>CALR</scp> mutations screening should not be studied in splanchnic vein thrombosis. <i>British Journal of Haematology</i> , 2015, 170, 588-589.	1.2	15
170	A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. <i>Leukemia Research</i> , 2019, 76, 1-10.	0.4	15
171	Thrombosis and antiphospholipid antibodies in patients with SARSâ€COVâ€2 infection (COVIDâ€19). <i>International Journal of Laboratory Hematology</i> , 2020, 42, e280-e282.	0.7	15
172	Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 6023-6033.	2.5	15
173	Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. <i>Haematologica</i> , 2021, 106, 3079-3089.	1.7	15
174	Drug Discovery Testing Compounds in Patient Samples by Automated Flow Cytometry. <i>SLAS Technology</i> , 2017, 22, 325-337.	1.0	14
175	Papainâ€treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with antiâ€CD38â€based therapies. <i>Transfusion Medicine</i> , 2019, 29, 193-196.	0.5	14
176	Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 998-1002.	0.5	14
177	Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. <i>Blood</i> , 2019, 134, 581-581.	0.6	14
178	A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2598-2609.	3.2	14
179	Dual-function stem molecular beacons to assess mRNA expression in AT-rich transcripts of <i>Plasmodium falciparum</i> . <i>BioTechniques</i> , 2004, 36, 488-494.	0.8	13
180	Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia. <i>Annals of Hematology</i> , 2012, 91, 1-7.	0.8	13

#	ARTICLE	IF	CITATIONS
181	Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations—An Extensive Replication of the Associations from the Candidate Gene Era. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 670-674.	1.1	13
182	How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?. <i>Transfusion</i> , 2018, 58, 1340-1347.	0.8	13
183	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. <i>Haematologica</i> , 2018, 103, e544-e548.	1.7	13
184	Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. <i>Cancer Medicine</i> , 2021, 10, 7629-7640.	1.3	13
185	VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study. <i>Blood</i> , 2018, 132, 126-126.	0.6	13
186	A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years.. <i>Blood</i> , 2009, 114, 3-3.	0.6	13
187	Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL). <i>Blood</i> , 2021, 138, 128-128.	0.6	13
188	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. <i>American Journal of Hematology</i> , 2022, , .	2.0	13
189	Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. <i>Leukemia Research Reports</i> , 2015, 4, 64-69.	0.2	12
190	Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity. <i>Pharmacogenomics</i> , 2017, 18, 1215-1223.	0.6	12
191	A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. <i>Haematologica</i> , 2018, 103, 880-889.	1.7	12
192	Evolving treatment patterns and outcomes in older patients (>=60 years) with AML: changing everything to change nothing?. <i>Leukemia</i> , 2021, 35, 1571-1585.	3.3	12
193	Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex). <i>Blood</i> , 2020, 136, 8-9.	0.6	12
194	Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial. <i>Blood</i> , 2012, 120, 334-334.	0.6	12
195	Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study. <i>Blood</i> , 2015, 126, 721-721.	0.6	12
196	Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDI-ASCT, Consolidation with Krd and Maintenance with Rd. <i>Blood</i> , 2021, 138, 1829-1829.	0.6	12
197	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. <i>Endocrine-Related Cancer</i> , 2015, 22, 545-559.	1.6	11
198	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. <i>British Journal of Haematology</i> , 2018, 183, 375-384.	1.2	11

#	ARTICLE	IF	CITATIONS
199	Collaborative intelligence and gamification for on-line malaria species differentiation. <i>Malaria Journal</i> , 2019, 18, 21.	0.8	11
200	Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. <i>Blood</i> , 2019, 133, 2664-2668.	0.6	11
201	Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. <i>Blood Cancer Journal</i> , 2019, 9, 36.	2.8	11
202	Immediate Effects of Dasatinib on the Migration and Redistribution of Na ⁺ ve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients. <i>Frontiers in Pharmacology</i> , 2019, 10, 1340.	1.6	11
203	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMENSE study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1803-1811.	0.6	11
204	Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with <i>in vivo</i> chemosensitivity. <i>British Journal of Haematology</i> , 2020, 189, 672-683.	1.2	11
205	Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study. <i>International Journal of Infectious Diseases</i> , 2021, 105, 487-494.	1.5	11
206	Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. <i>Blood</i> , 2021, 138, 1583-1589.	0.6	11
207	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. <i>Cancers</i> , 2021, 13, 4924.	1.7	11
208	Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 47-48.	0.6	11
209	Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8002-8002.	0.8	11
210	Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens. <i>Scientific Reports</i> , 2021, 11, 20745.	1.6	11
211	Malaria Hidden in a Patient with Diffuse Large-B-Cell Lymphoma and Sickle-Cell Trait. <i>Journal of Clinical Microbiology</i> , 2011, 49, 4401-4404.	1.8	10
212	A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics. <i>Blood Cancer Journal</i> , 2020, 10, 43.	2.8	10
213	Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. <i>Leukemia</i> , 2021, 35, 245-249.	3.3	10
214	Genetically determined telomere length and multiple myeloma risk and outcome. <i>Blood Cancer Journal</i> , 2021, 11, 74.	2.8	10
215	Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study. <i>International Journal of Infectious Diseases</i> , 2021, 105, 319-325.	1.5	10
216	Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1662.	1.7	10

#	ARTICLE	IF	CITATIONS
217	FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study. <i>Blood</i> , 2021, 138, 633-633.	0.6	10
218	Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03). <i>Leukemia and Lymphoma</i> , 2011, 52, 409-416.	0.6	9
219	Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness. <i>Blood</i> , 2019, 134, 836-840.	0.6	9
220	Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study. <i>Blood</i> , 2020, 136, 5-6.	0.6	9
221	Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study. <i>Blood</i> , 2021, 138, LBA-6-LBA-6.	0.6	9
222	Quantitative Assessment of PML-RARa and BCR-ABL by Two Real-Time PCR Instruments: Multiinstitutional Laboratory Trial. <i>Clinical Chemistry</i> , 2004, 50, 1088-1092.	1.5	8
223	Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma. <i>Leukemia Research</i> , 2011, 35, 431-437.	0.4	8
224	Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months. <i>Cancer Medicine</i> , 2015, 4, 995-1002.	1.3	8
225	Identification of miRSNPs associated with the risk of multiple myeloma. <i>International Journal of Cancer</i> , 2017, 140, 526-534.	2.3	8
226	PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase. <i>PLoS ONE</i> , 2017, 12, e0181366.	1.1	8
227	Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. <i>Leukemia</i> , 2018, 32, 2427-2434.	3.3	8
228	Exploring NKG2D and BCMA-CAR NK-92 for Adoptive Cellular Therapy to Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e24-e25.	0.2	8
229	Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype. <i>Scientific Reports</i> , 2020, 10, 5904.	1.6	8
230	Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. <i>British Journal of Haematology</i> , 2021, 192, 522-530.	1.2	8
231	Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 328-337.e1.	0.2	8
232	A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2018, 9, 26019-26031.	0.8	8
233	Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC). <i>Blood</i> , 2012, 120, 3764-3764.	0.6	8
234	Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. <i>Blood</i> , 2021, 138, 131-131.	0.6	8

#	ARTICLE	IF	CITATIONS
235	Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study. <i>Blood</i> , 2021, 138, 1677-1677.	0.6	8
236	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 68.	2.8	8
237	Prognostic value of tumoral ploidy in a series of Spanish patients with acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2000, 122, 124-130.	1.0	7
238	Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. <i>Annals of Hematology</i> , 2011, 90, 939-946.	0.8	7
239	Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. <i>British Journal of Haematology</i> , 2013, 163, 223-234.	1.2	7
240	Prognostic risk models for transplant decision-making in myelofibrosis. <i>Annals of Hematology</i> , 2018, 97, 813-820.	0.8	7
241	IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection. <i>Annals of Hematology</i> , 2020, 99, 2953-2956.	0.8	7
242	Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci?. <i>International Journal of Cancer</i> , 2021, 148, 1616-1624.	2.3	7
243	The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study. <i>Leukemia and Lymphoma</i> , 2021, 62, 2040-2043.	0.6	7
244	A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. <i>Annals of Hematology</i> , 2021, 100, 1497-1508.	0.8	7
245	The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. <i>Cancers</i> , 2021, 13, 2458.	1.7	7
246	Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 45-46.	0.6	7
247	Assessment of Treatment Response By Iife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial. <i>Blood</i> , 2021, 138, 544-544.	0.6	7
248	Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19. <i>International Journal of Infectious Diseases</i> , 2022, , .	1.5	7
249	Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8007-8007.	0.8	7
250	Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	7
251	The use of fluorescent molecular beacons in real time PCR of IgH gene rearrangements for quantitative evaluation of multiple myeloma. <i>International Journal of Laboratory Hematology</i> , 2004, 26, 31-35.	0.2	6
252	Surgical Resection of a Solitary Pancreatic Metastasis from Colorectal Cancer: A New Step to a Cure?. <i>Clinical Colorectal Cancer</i> , 2008, 7, 398-401.	1.0	6

#	ARTICLE	IF	CITATIONS
253	Influence of <i>MBL-2</i> mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2009, 50, 1283-1289.	0.6	6
254	Real-time PCR quantification of haematopoietic chimerism after transplantation: a comparison between TaqMan and hybridization probes technologies. <i>International Journal of Laboratory Hematology</i> , 2010, 32, e17-25.	0.7	6
255	Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?. <i>American Journal of Hematology</i> , 2014, 89, E206-11.	2.0	6
256	Detailed characterization of <i>MLH1</i> p. <i>D41H</i> and p. <i>N710D</i> variants coexisting in a Lynch syndrome family with conserved <i>MLH1</i> expression tumors. <i>Clinical Genetics</i> , 2015, 87, 543-548.	1.0	6
257	Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 815-819.	1.5	6
258	The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. <i>British Journal of Haematology</i> , 2019, 186, 263-268.	1.2	6
259	Fatal graft-versus-host disease after allogeneic stem cell transplantation in a patient recently exposed to nivolumab. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 502-506.	0.5	6
260	Natural killer cells efficiently target multiple myeloma clonogenic tumor cells. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2911-2924.	2.0	6
261	Deep Sequencing Reveals Oligoclonality At The Immunoglobulin Locus In Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 401-401.	0.6	6
262	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. <i>Blood</i> , 2013, 122, 743-743.	0.6	6
263	Comparison of Sequential Vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts with Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. <i>Blood</i> , 2014, 124, 178-178.	0.6	6
264	Simplifying the detection of <i>MUTYH</i> mutations by high resolution melting analysis. <i>BMC Cancer</i> , 2010, 10, 408.	1.1	5
265	Efficacy and safety of reduced-intensity induction therapy with a bortezomib-based regimen in elderly patients with multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 147-154.	1.1	5
266	Acute myeloid leukemia and transcription factors: role of erythroid Kr ⁴ ppel-like factor (EKLF). <i>Cancer Cell International</i> , 2012, 12, 25.	1.8	5
267	Use of <i>Sorafenib</i> as an effective treatment in an <i>AML</i> patient carrying a new point mutation affecting the <i>Juxtamembrane</i> domain of <i>FLT3</i> . <i>British Journal of Haematology</i> , 2012, 158, 555-558.	1.2	5
268	Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor. <i>Annals of Hematology</i> , 2015, 94, 1237-1239.	0.8	5
269	Low expression of <i>CD39</i> and <i>CD73</i> genes in centenarians compared with octogenarians. <i>Immunity and Ageing</i> , 2017, 14, 11.	1.8	5
270	Microengineering double layer hydrogel structures towards the recapitulation of the hematopoietic stem cell niche. <i>Science Bulletin</i> , 2018, 63, 1319-1323.	4.3	5

#	ARTICLE	IF	CITATIONS
271	The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data. BMC Cancer, 2019, 19, 1005.	1.1	5
272	Timing treatment for smoldering myeloma: is earlier better?. Expert Review of Hematology, 2019, 12, 345-354.	1.0	5
273	<p>Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain</p>. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 683-694.	0.7	5
274	Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms. Haematologica, 2019, 104, 937-946.	1.7	5
275	Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma. Cancers, 2020, 12, 3304.	1.7	5
276	Droplet Microfluidics for the ex Vivo Expansion of Human Primary Multiple Myeloma Cells. Micromachines, 2020, 11, 261.	1.4	5
277	Long-Term Human Hematopoietic Stem Cell Culture in Microdroplets. Micromachines, 2021, 12, 90.	1.4	5
278	Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. Transplantation and Cellular Therapy, 2021, 27, 493.e1-493.e8.	0.6	5
279	Transcriptomic Profiling of Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): A New Model to Understand Disease Dissemination. Blood, 2018, 132, 245-245.	0.6	5
280	Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing. Blood, 2015, 126, 371-371.	0.6	5
281	xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>̂²</mml:mi></mml:math>-Thalassaemia Major in a Spanish Patient due to a Compound Heterozygosity for CD39<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mtext>C</mml:mtext><mml:mo>â†'</mml:mo><mml:mtext>T</mml:mtext><mml:mo>â†'</mml:mo><mml:mtext>A</mml:mtext><mml:mo>â†'</mml:mo><mml:mtext>C</mml:mtext></mml:math>	0.6	4
282	Wilms Tumor 1 gene expression levels improve risk stratification in <sc>AML</sc> patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology. British Journal of Haematology, 2018, 181, 542-546.	1.2	4
283	Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy. Antioxidants, 2019, 8, 508.	2.2	4
284	Comprehensive Custom NGS Panel Validation for the Improvement of the Stratification of B-Acute Lymphoblastic Leukemia Patients. Journal of Personalized Medicine, 2020, 10, 137.	1.1	4
285	TYK2 Variants in B-Acute Lymphoblastic Leukaemia. Genes, 2020, 11, 1434.	1.0	4
286	Induction with Fludarabine, Cyclophosphamide and Rituximab Followed by Maintenance with Rituximab: Results of a Prospective Study in 75 Patients (LNHF-03).. Blood, 2006, 108, 2762-2762.	0.6	4
287	Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. Blood, 2013, 122, 403-403.	0.6	4
288	Chronic Myeloid Leukemia (CML) Patients With Atypical e1a2 P190 BCR-ABL Translocation Show a Poor Response To Therapy With Tyrosine Kinase Inhibitors (TKI). Blood, 2013, 122, 5193-5193.	0.6	4

#	ARTICLE	IF	CITATIONS
289	Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial. <i>Blood</i> , 2014, 124, 3390-3390.	0.6	4
290	Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials. <i>Blood</i> , 2015, 126, 19-19.	0.6	4
291	Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma. <i>Blood</i> , 2016, 128, 4505-4505.	0.6	4
292	The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach. <i>Diagnostics</i> , 2021, 11, 2020.	1.3	4
293	Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience. <i>Blood</i> , 2021, 138, 3775-3775.	0.6	4
294	Ponatinib and Chemotherapy in Adults with <i>De Novo</i> Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial. <i>Blood</i> , 2021, 138, 1230-1230.	0.6	4
295	Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells. <i>Frontiers in Oncology</i> , 2021, 11, 783703.	1.3	4
296	JAK2 exon 12 mutations were not found in liver transplant recipients with or without pretransplant portal vein thrombosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 362-363.	0.8	3
297	Antiphospholipid syndrome in a patient suffering from congenital dyserythropoietic anemia type III. <i>Annals of Hematology</i> , 2015, 94, 1411-1412.	0.8	3
298	Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets. <i>Leukemia and Lymphoma</i> , 2016, 57, 134-142.	0.6	3
299	Common gene variants within 3' untranslated regions as modulators of multiple myeloma risk and survival. <i>International Journal of Cancer</i> , 2021, 148, 1887-1894.	2.3	3
300	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. <i>International Journal of Cancer</i> , 2021, 149, 327-336.	2.3	3
301	Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 3189.	1.7	3
302	Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics. <i>Blood</i> , 2018, 132, 112-112.	0.6	3
303	Phase 2 Study Of Bendamustine, Bortezomib (Velcade) and Prednisone (BVP) For Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 2155-2155.	0.6	3
304	Prognostic Impact Of Comorbidity In Multiple Myeloma. <i>Blood</i> , 2013, 122, 5340-5340.	0.6	3
305	OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S3-S4.	0.2	3
306	Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2021, 138, 3528-3528.	0.6	3

#	ARTICLE	IF	CITATIONS
307	A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper. <i>Clinical and Translational Oncology</i> , 2022, 24, 968-980.	1.2	3
308	Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 797209.	2.2	3
309	Typical chronic myelogenous leukemia with e19a2 BCR/ABL transcript. Report of two cases. <i>Haematologica</i> , 2002, 87, ELT35.	1.7	3
310	Infusion of haploidentical NKG2D-CAR-T_{CD45RA} cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits. <i>Leukemia and Lymphoma</i> , 2022, 63, 1970-1974.	0.6	3
311	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. <i>Leukemia Research</i> , 2022, 115, 106821.	0.4	3
312	Prognostic implications of MRD assessment in multiple myeloma patients: comparison of Next-Generation Sequencing and Next-Generation Flow. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e47.	0.2	2
313	Polycythemia Vera and Essential Thrombocythemia Patients Exhibit Unique Serum Metabolic Profiles Compared to Healthy Individuals and Secondary Thrombocytosis Patients. <i>Cancers</i> , 2021, 13, 482.	1.7	2
314	Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera. <i>Scientific Reports</i> , 2021, 11, 209.	1.6	2
315	A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline. <i>Leukemia</i> , 2021, 35, 3295-3298.	3.3	2
316	Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110393.	1.1	2
317	Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Preliminary Results of Ponalfil Clinical Trial. <i>Blood</i> , 2019, 134, 3874-3874.	0.6	2
318	The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD). <i>Blood</i> , 2019, 134, 509-509.	0.6	2
319	Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib (V) Lenalidomide (R) and Dexamethasone(d) Combined Therapy for Newly Diagnosed Multiple Myeloma (NDMM): Results from a Phase 1b Feasibility/Safety Study. <i>Blood</i> , 2020, 136, 15-16.	0.6	2
320	Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials. <i>Blood</i> , 2010, 116, 1910-1910.	0.6	2
321	Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 686-686.	0.6	2
322	Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study. <i>Blood</i> , 2014, 124, 3457-3457.	0.6	2
323	Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years. <i>Blood</i> , 2015, 126, 1848-1848.	0.6	2
324	Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 367-367.	0.6	2

#	ARTICLE	IF	CITATIONS
325	Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hybridization (FISH). <i>Blood</i> , 2015, 126, 4243-4243.	0.6	2
326	A Novel Evolutionary Pattern Revealed Using Deep Sequencing of Immunoglobulin Loci at Diagnosis and over the Course of Treatment in Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 238-238.	0.6	2
327	Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 3283-3283.	0.6	2
328	Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group. <i>Blood</i> , 2016, 128, 4503-4503.	0.6	2
329	Non-Invasive Genetic Profiling Is Highly Applicable in Multiple Myeloma (MM) through Characterization of Circulating Tumor Cells (CTCs). <i>Blood</i> , 2016, 128, 801-801.	0.6	2
330	The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients. <i>Blood</i> , 2015, 126, 4181-4181.	0.6	2
331	Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies. <i>Blood</i> , 2021, 138, 541-541.	0.6	2
332	MPL S505C enhances driver mutations at W515 in essential thrombocythemia. <i>Blood Cancer Journal</i> , 2021, 11, 188.	2.8	2
333	Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates. <i>Blood</i> , 2020, 136, 18-19.	0.6	2
334	Minimal Residual Disease Monitoring from Liquid Biopsy By Next Generation Sequencing in Follicular Lymphoma Patients. <i>Blood</i> , 2020, 136, 31-33.	0.6	2
335	Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry. <i>Blood</i> , 2020, 136, 7-8.	0.6	2
336	Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19. <i>Biomedicines</i> , 2022, 10, 630.	1.4	2
337	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	1.1	2
338	Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8033-8033.	0.8	2
339	Application of Self-Quenched JH Consensus Primers for Real-Time Quantitative PCR of IGH Gene to Minimal Residual Disease Evaluation in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 364-370.	1.2	1
340	Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S75-S76.	0.6	1
341	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8034-8034.	0.8	1
342	VDJH Gene Repertoire Analysis in Multiple Myeloma (MM) Patients: Correlation with Clinical Data. <i>Blood</i> , 2018, 132, 4446-4446.	0.6	1

#	ARTICLE	IF	CITATIONS
343	Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM). Blood, 2019, 134, 1876-1876.	0.6	1
344	Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone. Blood, 2020, 136, 43-44.	0.6	1
345	Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immucell Study. Blood, 2020, 136, 1-2.	0.6	1
346	Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials. Blood, 2015, 126, 2962-2962.	0.6	1
347	What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity. Blood, 2015, 126, 725-725.	0.6	1
348	Safety and Efficacy of Dasatinib Treatment Change for Patients Previously Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study. Blood, 2016, 128, 5450-5450.	0.6	1
349	The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators. Blood, 2016, 128, 5688-5688.	0.6	1
350	Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the "Watch and Wait" Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials. Blood, 2012, 120, 3768-3768.	0.6	1
351	Characterization of Subclonal Changes Along Progression in Multiple Myeloma.. Blood, 2012, 120, 2924-2924.	0.6	1
352	Development of a High-Throughput Screening Assay with Nurse-like Cell-Based Microenvironment in Chronic Lymphoid Leukemia Cells.. Blood, 2014, 124, 3639-3639.	0.6	1
353	Ruxolitinib in Combination with Nilotinib and Prednisolone, a New Synergistic Approach to Treat Myelofibrosis. Blood, 2014, 124, 903-903.	0.6	1
354	Preclinical Evidence That Trametinib Enhances the Response to Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia. Blood, 2016, 128, 1581-1581.	0.6	1
355	The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival. Blood, 2016, 128, 375-375.	0.6	1
356	Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM). Blood, 2019, 134, 3064-3064.	0.6	1
357	The Role of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies. Blood, 2019, 134, 5560-5560.	0.6	1
358	NKG2D CAR-Expressing Lymphocytes Target Acute Myeloid Leukemia Cells. Blood, 2019, 134, 2667-2667.	0.6	1
359	Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. Blood, 2019, 134, 1852-1852.	0.6	1
360	Microfluidic-assisted engineering of multi-layered microcapsules for 3D stem cell culture. , 2020, , .		1

#	ARTICLE	IF	CITATIONS
361	P-226: Clinical outcomes of Multiple Myeloma patients after anti-CD38 monoclonal antibodies failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S164-S165.	0.2	1
362	Acute and Post-Acute COVID-19 Severity and Mortality in Patients with Hematologic Malignancies: A Population-Based Registry Study. <i>Blood</i> , 2021, 138, 186-186.	0.6	1
363	Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic. <i>Blood</i> , 2021, 138, 2719-2719.	0.6	1
364	Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony. <i>Blood</i> , 2021, 138, 2617-2617.	0.6	1
365	Impact of Measurable Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC): A Real-World Study in 1,076 Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 13-15.	0.6	1
366	Detection of Emerging Resistant Clones in Philadelphia-Positive Leukemia Patients Exposed to Tyrosine Kinase Inhibitors. Correlation of cDNA and Gdna Approaches. <i>Blood</i> , 2020, 136, 6-8.	0.6	1
367	Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment. <i>Blood</i> , 2020, 136, 29-30.	0.6	1
368	Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in Europe between 1995-2018: An EBMT Retrospective Analysis. <i>Blood</i> , 2020, 136, 38-39.	0.6	1
369	Clinical Validation of a NGS Capture Panel to Identify Mutations, Copy Number Variations and Translocations in Patients with Multiple Myeloma. <i>Blood</i> , 2020, 136, 13-14.	0.6	1
370	P-007: Exploring a safety switch in NKG2D and BCMA CAR NK-92MI immunotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S42-S43.	0.2	1
371	P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S109-S110.	0.2	1
372	427 Hematotoxicity potential of new drug candidates measured in hematopoietic progenitors in bone marrow samples. <i>European Journal of Cancer</i> , 2014, 50, 136-137.	1.3	0
373	230 High correlation between clinical responses to first line AML patients treated with cytarabine and idarubicin and their pharmacological profiles in patient samples measured by ExviTech. <i>European Journal of Cancer</i> , 2014, 50, 77-78.	1.3	0
374	Efficient Identification of Response to Cytarabine Idarubicin in Newly Diagnosed Acute Myeloid Leukemia by a New Individualized Medicine Test Based on ex vivo Pharmacology. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S118-S119.	0.2	0
375	The Pharmacological Profiles of Approved Cytotoxic AML Treatments ex vivo Identifies Sensitive vs Resistant Treatments in Patient's Leukemic Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S117.	0.2	0
376	1st Line AML Equivalent Treatments Cytarabine Plus an Anthracyclin (Ida, Dau, Mit) Show Alternative Sensitive/Resistant Profiles in ex vivo Patient Sample Chemosensitivity; Could Personalizing be the Key Selection Criterion?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S117-S118.	0.2	0
377	Drug induced depletion of myeloid progenitors in bone marrow samples as an ex vivo estimation of hematotoxicity. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S240-S241.	0.2	0
378	Prognostic Significance of Copy Number Alterations in B-lineage Adult Acute Lymphoblastic Leukemia Patients Enrolled in Risk-adapted Protocols from the PETHEMA Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S173-S174.	0.2	0

#	ARTICLE	IF	CITATIONS
379	Multiple Infusions of Autologous Activated and Expanded Natural Killer Cells: A New Therapeutic Option for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e297-e298.	0.2	0
380	The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients With MDS/AML-Related Somatic Mutations And Inferior Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e11.	0.2	0
381	Mutations in DNA Methylation Pathway and Number of Driver Mutations Predict Response to Azacitidine in Myelodysplastic Syndromes. <i>Leukemia Research</i> , 2017, 55, S61.	0.4	0
382	Quantification of proteins from CD138-purified myeloma cells using the capillary nano-immunoassay technology is a better predictor of survival than the corresponding gene expression value. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e4-e5.	0.2	0
383	ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI): Phase 1 Update. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S326-S327.	0.2	0
384	Clinical relevance of Minimal residual Disease assessment by NGS in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e179-e180.	0.2	0
385	Prolonged Lenalidomide Maintenance Therapy Improves the Quality and Deep of Response in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e285-e286.	0.2	0
386	Detailed Phenotypic, Molecular and Functional Profiling of Myeloid Derived Suppressor Cells (MDSCs) in the Tumor Immune Micro-Environment (TIME) of Multiple Myeloma (MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e97-e98.	0.2	0
387	Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e351.	0.2	0
388	ALL-154: t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S270-S271.	0.2	0
389	Topic: ASO6-Prognosis/ASO6a-Prognostic factors of outcome and risk assessment. <i>Leukemia Research</i> , 2021, 108, 106681.37.	0.4	0
390	Poster: IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S245.	0.2	0
391	IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S403-S404.	0.2	0
392	Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology. <i>Leukemia Research</i> , 2021, 108, 106613.	0.4	0
393	Discrepancy between Phenotype and Genotype for Factor V Leiden Mutation in Recipients of Liver Transplant.. <i>Blood</i> , 2005, 106, 4120-4120.	0.6	0
394	Influence of GST Gene Polimorphisms in the Develoement of Liver Sinusoidal Obstructive Syndrome in Patients with Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 3084-3084.	0.6	0
395	Cohort Study of Thrombophilia and Thombotics Events in Recipients of Liver Transplantation and Their Respective Donors.. <i>Blood</i> , 2006, 108, 4093-4093.	0.6	0
396	Comparison of the MagNA pure LC automated system and the RiboPure-Blood RNA manual method for RNA extraction from multiple myeloma bone marrow samples conserved in an RNA stabilizer. <i>International Journal of Laboratory Hematology</i> , 2006, .	0.2	0

#	ARTICLE	IF	CITATIONS
397	FLT3 Mutations in a Large Series of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy.. Blood, 2006, 108, 2348-2348.	0.6	0
398	Importance of JAK2 V617F Allele Burden in the Diagnosis of Myeloproliferative Diseases and Its Association to Age.. Blood, 2007, 110, 4654-4654.	0.6	0
399	High Throughput Screening, With a Flow Cytometry Automated Platform (Ex vivo Biotech), To Identify Potential Combination Partners, For The JAK 2 Inhibitor Ruxolitinib. Blood, 2013, 122, 2534-2534.	0.6	0
400	FLT3, PIM and CXCR4 Expression In Acute Myeloid Leukemia. Blood, 2013, 122, 4957-4957.	0.6	0
401	BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The E14-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent Of TP53 Mutation Status. Blood, 2013, 122, 876-876.	0.6	0
402	Prognostic Significance Of Copy Number Alterations In B-Lineage Adult Acute Lymphoblastic Leukemia Patients Enrolled In Risk-Adapted Protocols From The Pethema Group. Blood, 2013, 122, 2556-2556.	0.6	0
403	Pharmacological Profile Of Cytarabine and Idarubicin In Patient Samples (ex vivo) With Newly Diagnosed Acute Myeloid Leukemia Identifies Responders Vs Non Responders. Blood, 2013, 122, 3923-3923.	0.6	0
404	Personalizing Therapies With Ex Vivo Pharmacological Responses May Uncover The Differences Between IDA-DNR-MIT Among European AML Protocols. Blood, 2013, 122, 1294-1294.	0.6	0
405	Prognostic Value Of Deep Sequencing Approach For Minimal Residual Disease (MRD) Detection In Multiple Myeloma Patients. Blood, 2013, 122, 1848-1848.	0.6	0
406	Abstract 5078: Genome wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. , 2014, , .		0
407	Autologous Activated and Expanded Natural Killer Cells Kill Clonogenic Myeloma Cells: A New Therapeutic Option for Multiple Myeloma. Blood, 2014, 124, 3467-3467.	0.6	0
408	Novel Assay for Ex Vivo Evaluation of Antiproliferative Effect of Hypomethylating Agents 5-Azacytidine and Decitabine in AML Patient Samples. Blood, 2014, 124, 5311-5311.	0.6	0
409	Novel Ex Vivo Assay Measures Drug-Induced Depletion of Hematopoietic Progenitors As an Estimate of Hematotoxicity. Blood, 2014, 124, 5785-5785.	0.6	0
410	Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium. Blood, 2014, 124, 2044-2044.	0.6	0
411	Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group. Blood, 2014, 124, 3798-3798.	0.6	0
412	The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis. Blood, 2014, 124, 3421-3421.	0.6	0
413	Chronic Lymphocytic Leukemia Patients Harbor Very Low Frequency Stereotypic Immunoglobulin CDR3 Sequences. Blood, 2014, 124, 5635-5635.	0.6	0
414	Wilmsâ€™ Tumor 1 Expression Levels in Bone Marrow after Induction and/or Consolidation Therapy Allow a Better Stratification of Patients and Improves Treatment in Adult AML. Blood, 2014, 124, 1036-1036.	0.6	0

#	ARTICLE	IF	CITATIONS
415	Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens. <i>Blood</i> , 2014, 124, 2108-2108.	0.6	0
416	Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase. <i>Blood</i> , 2015, 126, 2791-2791.	0.6	0
417	Autologous Activated and Expanded Natural Killer Cells Are Safe and Clinically Actives in Multiple Myeloma. <i>Blood</i> , 2015, 126, 1856-1856.	0.6	0
418	A Way to Individualized Therapy in Acute Myeloid Leukemia (AML): NGS Mutational Profile and Ex Vivo Pharmacological Test (Ex-viTech). <i>Blood</i> , 2015, 126, 1376-1376.	0.6	0
419	hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML. <i>Blood</i> , 2015, 126, 439-439.	0.6	0
420	Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 2963-2963.	0.6	0
421	An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL. <i>Blood</i> , 2015, 126, 2485-2485.	0.6	0
422	Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression. <i>Blood</i> , 2015, 126, 4015-4015.	0.6	0
423	Simplified in-House Deep Sequencing Method of Immunoglobulin Genes for Minimal Residual Disease Quantification and Risk Stratification in Multiple Myeloma. <i>Blood</i> , 2015, 126, 2972-2972.	0.6	0
424	High Correlation Clinical Responses to 1st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test. <i>Blood</i> , 2015, 126, 4837-4837.	0.6	0
425	Donor Chimerism, Kir Ligand Mismatch and Cytokine Levels (Tnfi±, Il17, Gmcsf, Il1β) and their Association with Graft Rejection in Liver Transplant Recipients. <i>Journal of Clinical & Cellular Immunology</i> , 2016, 07, .	1.5	0
426	Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 5281-5281.	0.6	0
427	Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with This in Spain. <i>Blood</i> , 2016, 128, 3074-3074.	0.6	0
428	Nilotinib Plus Ruxolitinib Produces Anti-Fibrotic Effect. <i>Blood</i> , 2016, 128, 5497-5497.	0.6	0
429	Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial. <i>Blood</i> , 2016, 128, 2078-2078.	0.6	0
430	Abstract B012: A novel in vitro approach elucidates a new mode of cytotoxic action of bispecific antibodies on hematologic malignancies. , 2018, , .		0
431	Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial. <i>Blood</i> , 2018, 132, 474-474.	0.6	0
432	hnRNP K: A Regulator of Global Transcription and Translation That Drives Lymphomagenesis. <i>Blood</i> , 2018, 132, 1346-1346.	0.6	0

#	ARTICLE	IF	CITATIONS
433	Understanding the Cellular Origin and Pathogenic Transcriptional Programs in Multiple Myeloma (MM) and Light-Chain Amyloidosis (AL) through the Dissection of the Normal Plasma Cell (PC) Development. Blood, 2018, 132, 188-188.	0.6	0
434	Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor. Blood, 2018, 132, 4503-4503.	0.6	0
435	Multidimensional Immunophenotyping Identifies Hallmarks of Systemic Light-Chain Amyloidosis (AL) and Maps the Disease in the Crossroad between MGUS and Multiple Myeloma (MM). Blood, 2018, 132, 3170-3170.	0.6	0
436	Minimal residual disease clinical monitoring and depth of response in multiple myeloma.. Journal of Clinical Oncology, 2019, 37, 8026-8026.	0.8	0
437	Abstract CT080: Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104). , 2019, . .		0
438	Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application. Blood, 2019, 134, 4398-4398.	0.6	0
439	Proposal of a "2-Step-Algorithm" for the Screening of Myeloproliferative Neoplasms in Individuals with Erythrocytosis. Blood, 2019, 134, 4187-4187.	0.6	0
440	Clonal Competition Models to Understand Progression and Resistance in Myeloma. Blood, 2019, 134, 1807-1807.	0.6	0
441	Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime. Blood, 2019, 134, 3325-3325.	0.6	0
442	Different Clinical Implications of Kinase Domain BCR-ABL1 Variants Detected in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia Patients. Blood, 2019, 134, 5368-5368.	0.6	0
443	Increase of Mitochondrial Activity Contributes to the Bortezomib-Relapsed in Multiple Myeloma, a Novel Therapeutic Opportunity. Blood, 2019, 134, 4408-4408.	0.6	0
444	Fatal Outcome of COVID-19 Reactivation in a Patient With Multiple Myeloma After Reintroduction of Myeloma Therapy. Clinical Infection and Immunity, 2020, 5, 77-81.	0.1	0
445	P-148: Real-life analysis of the multiple myeloma patient's survival in a third-level hospital. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S116.	0.2	0
446	OAB-035: Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMUNOCeLL study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S22-S23.	0.2	0
447	P-003: Improving NK cell function in Multiple Myeloma with NKTR-255, a novel polymer-conjugated human IL-15. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S40-S41.	0.2	0
448	Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group. Blood, 2021, 138, 1302-1302.	0.6	0
449	Triple Combination of Ruxolutinib, Nilotinib and Prednisone Is Safe and Shows Promising Activity for the Treatment of Myelofibrosis Patients, Results of a Phase Ib Clinical Trial (RUNIC). Blood, 2021, 138, 3655-3655.	0.6	0
450	Potential Utility of Circulating Tumor DNA Monitoring in Primary Mediastinal B-Cell Lymphoma Treated with R-DA-EPOCH. Blood, 2021, 138, 4491-4491.	0.6	0

#	ARTICLE	IF	CITATIONS
451	Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Blood</i> , 2021, 138, 2818-2818.	0.6	0
452	Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4. <i>Blood</i> , 2021, 138, 1307-1307.	0.6	0
453	Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Patterns from Dysplasia to Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 520-520.	0.6	0
454	Usability and Performance Testing of Pointcheckâ„¢: A Noninvasive Neutropenia Screening Device for Chemotherapy Outpatients. <i>Blood</i> , 2021, 138, 4924-4924.	0.6	0
455	Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study. <i>Blood</i> , 2021, 138, 3438-3438.	0.6	0
456	The Spliceosome As a New Therapeutic Target in Cytarabine-Resistant Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3334-3334.	0.6	0
457	Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1631-1631.	0.6	0
458	Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial. <i>Blood</i> , 2020, 136, 32-32.	0.6	0
459	Study of the Role of Splicing Factor SRRM2 in Cytarabine Treatment Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
460	Validation of the High-Risk Prognostic Score Defined By the Presence of Mutations in NRAS or TP53 in a Cohort of 497 Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 4-5.	0.6	0
461	Differences in the Mutational Landscape of Myeloid Malignancies (acute myeloid leukemia,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 TFS 136, 41-42.	0.6	0
462	A Machine Learning Approach for the Differential Diagnosis between Sars-COV19 Infection and Influenza Viruses with Hematological Morphologic DATA (CELL MORPHOLOGIC DATA). <i>Blood</i> , 2020, 136, 43-43.	0.6	0
463	OAB-056: A machine learning model based on tumor and immune biomarkers to predict undetectable measurable residual disease (MRD) in transplant-eligible multiple myeloma (MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S35.	0.2	0
464	Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 2817.	1.7	0